Trade Asensus Surgical, Inc. - ASXC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0442 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.7236 |
Open* | 0.7328 |
1-Year Change* | -4.83% |
Day's Range* | 0.6666 - 0.7332 |
52 wk Range | 0.28-0.92 |
Average Volume (10 days) | 2.00M |
Average Volume (3 months) | 25.13M |
Market Cap | 176.47M |
P/E Ratio | -100.00K |
Shares Outstanding | 236.84M |
Revenue | 7.10M |
EPS | -0.31 |
Dividend (Yield %) | N/A |
Beta | 1.79 |
Next Earnings Date | Feb 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 0.6683 | -0.0381 | -5.39% | 0.7064 | 0.7403 | 0.6583 |
Feb 7, 2023 | 0.7236 | 0.0678 | 10.34% | 0.6558 | 0.7380 | 0.6483 |
Feb 6, 2023 | 0.6688 | 0.0803 | 13.64% | 0.5885 | 0.6853 | 0.5885 |
Feb 3, 2023 | 0.7311 | 0.0070 | 0.97% | 0.7241 | 0.7748 | 0.7181 |
Feb 2, 2023 | 0.7201 | -0.0244 | -3.28% | 0.7445 | 0.7723 | 0.7167 |
Feb 1, 2023 | 0.7239 | -0.0658 | -8.33% | 0.7897 | 0.7948 | 0.6683 |
Jan 31, 2023 | 0.7715 | -0.0313 | -3.90% | 0.8028 | 0.8268 | 0.7680 |
Jan 30, 2023 | 0.7980 | 0.0200 | 2.57% | 0.7780 | 0.8346 | 0.7780 |
Jan 27, 2023 | 0.7981 | -0.0010 | -0.13% | 0.7991 | 0.8546 | 0.7580 |
Jan 26, 2023 | 0.8093 | 0.1239 | 18.08% | 0.6854 | 0.8294 | 0.6683 |
Jan 25, 2023 | 0.6726 | 0.0043 | 0.64% | 0.6683 | 0.6882 | 0.6583 |
Jan 24, 2023 | 0.6677 | -0.0277 | -3.98% | 0.6954 | 0.6954 | 0.6611 |
Jan 23, 2023 | 0.6597 | 0.0114 | 1.76% | 0.6483 | 0.7028 | 0.6483 |
Jan 20, 2023 | 0.6416 | -0.0167 | -2.54% | 0.6583 | 0.6803 | 0.6284 |
Jan 19, 2023 | 0.6481 | 0.0024 | 0.37% | 0.6457 | 0.6660 | 0.6084 |
Jan 18, 2023 | 0.5981 | -0.0973 | -13.99% | 0.6954 | 0.7099 | 0.5885 |
Jan 17, 2023 | 0.6583 | 0.0424 | 6.88% | 0.6159 | 0.7172 | 0.6084 |
Jan 13, 2023 | 0.5865 | 0.1246 | 26.98% | 0.4619 | 0.5931 | 0.4588 |
Jan 12, 2023 | 0.4682 | 0.0252 | 5.69% | 0.4430 | 0.4740 | 0.4291 |
Jan 11, 2023 | 0.4409 | 0.0039 | 0.89% | 0.4370 | 0.4486 | 0.4370 |
Asensus Surgical, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 1.519 | 7.111 | 24.102 | 8.531 | 3.175 | 8.232 |
Revenue | 1.519 | 7.111 | 24.102 | 8.531 | 3.175 | 8.232 |
Cost of Revenue, Total | 1.069 | 6.727 | 16.171 | 20.731 | 5.166 | 11.096 |
Gross Profit | 0.45 | 0.384 | 7.931 | -12.2 | -1.991 | -2.864 |
Total Operating Expense | 125.168 | 69.038 | 73.254 | 163.106 | 63.564 | 70.004 |
Selling/General/Admin. Expenses, Total | 19.964 | 29.811 | 39.59 | 46.772 | 27.201 | 32.718 |
Research & Development | 29.273 | 21.989 | 21.823 | 22.468 | 16.621 | 19.348 |
Depreciation / Amortization | 6.967 | 7.858 | 10.868 | 10.301 | 10.801 | 11.254 |
Unusual Expense (Income) | 67.413 | 0 | -14.187 | 72.387 | 0.851 | -2.847 |
Other Operating Expenses, Total | 0.482 | 2.653 | -1.011 | -9.553 | 2.924 | -1.565 |
Operating Income | -123.649 | -61.927 | -49.152 | -154.575 | -60.389 | -61.772 |
Interest Income (Expense), Net Non-Operating | -1.889 | -85.869 | -17.128 | -1.783 | -0.32 | -1.761 |
Other, Net | 0.035 | -0.3 | 1.126 | -0.967 | -0.119 | 1.296 |
Net Income Before Taxes | -125.503 | -148.096 | -65.154 | -157.325 | -60.828 | -62.237 |
Net Income After Taxes | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Net Income Before Extra. Items | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Net Income | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Income Available to Common Excl. Extra. Items | -119.98 | -144.796 | -61.777 | -154.201 | -60.023 | -62.462 |
Income Available to Common Incl. Extra. Items | -119.98 | -144.796 | -61.777 | -154.201 | -60.023 | -62.462 |
Diluted Net Income | -119.98 | -144.796 | -61.777 | -154.201 | -60.023 | -62.462 |
Diluted Weighted Average Shares | 8.62962 | 11.4418 | 15.9384 | 17.737 | 70.809 | 226.96 |
Diluted EPS Excluding Extraordinary Items | -13.9033 | -12.655 | -3.87599 | -8.69375 | -0.84767 | -0.27521 |
Diluted Normalized EPS | -8.8256 | -12.655 | -4.45456 | -5.88489 | -0.83986 | -0.28337 |
Total Extraordinary Items | 0 | |||||
Total Adjustments to Net Income | -0.711 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 2.083 | 1.102 | 2.571 | 2.476 | 1.066 |
Revenue | 2.083 | 1.102 | 2.571 | 2.476 | 1.066 |
Cost of Revenue, Total | 3.112 | 2.347 | 3.35 | 2.287 | 1.823 |
Gross Profit | -1.029 | -1.245 | -0.779 | 0.189 | -0.757 |
Total Operating Expense | 17.496 | 14.339 | 20.009 | 18.16 | 20.019 |
Selling/General/Admin. Expenses, Total | 7.045 | 7.41 | 9.108 | 9.155 | 9.252 |
Research & Development | 4.215 | 4.089 | 4.469 | 6.575 | 6.428 |
Depreciation / Amortization | 2.867 | 2.862 | 2.804 | 2.721 | 2.67 |
Unusual Expense (Income) | 0 | -2.847 | 0 | 0 | |
Other Operating Expenses, Total | 0.257 | 0.478 | 0.278 | -2.578 | -0.154 |
Operating Income | -15.413 | -13.237 | -17.438 | -15.684 | -18.953 |
Interest Income (Expense), Net Non-Operating | -1.936 | 0.074 | 0.057 | 0.044 | 0.055 |
Other, Net | -0.029 | -0.007 | 1.344 | -0.012 | -0.146 |
Net Income Before Taxes | -17.378 | -13.17 | -16.037 | -15.652 | -19.044 |
Net Income After Taxes | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Net Income Before Extra. Items | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Net Income | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
Income Available to Common Excl. Extra. Items | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Income Available to Common Incl. Extra. Items | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Diluted Net Income | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Diluted Weighted Average Shares | 204.992 | 233.25 | 234.337 | 234.94 | 235.892 |
Diluted EPS Excluding Extraordinary Items | -0.08459 | -0.05647 | -0.06857 | -0.0676 | -0.08109 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.08459 | -0.06441 | -0.06857 | -0.0676 | -0.08109 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 38.016 | 112.994 | 101.583 | 27.955 | 34.013 | 113.297 |
Cash and Short Term Investments | 24.165 | 91.217 | 72.851 | 9.598 | 16.363 | 98.391 |
Cash & Equivalents | 24.165 | 91.217 | 21.061 | 9.598 | 16.363 | 18.129 |
Total Receivables, Net | 1.976 | 3.038 | 8.595 | 3.336 | 3.985 | 2.06 |
Accounts Receivable - Trade, Net | 0.621 | 1.536 | 8.56 | 0.62 | 1.115 | 0.749 |
Total Inventory | 7.883 | 10.817 | 10.941 | 10.653 | 10.034 | 8.634 |
Prepaid Expenses | 3.992 | 7.922 | 9.196 | 4.368 | 3.631 | 3.255 |
Total Assets | 176.249 | 250.251 | 239.307 | 74.779 | 78.258 | 186.473 |
Property/Plant/Equipment, Total - Net | 5.772 | 6.67 | 6.337 | 7.006 | 11.542 | 16.319 |
Property/Plant/Equipment, Total - Gross | 12.345 | 15.888 | 17.499 | 17.974 | 25.802 | 26.008 |
Accumulated Depreciation, Total | -6.573 | -9.218 | -11.162 | -10.968 | -14.26 | -9.689 |
Goodwill, Net | 68.697 | 71.368 | 80.131 | 0 | ||
Intangibles, Net | 53.01 | 52.638 | 50.463 | 31.066 | 22.267 | 9.892 |
Note Receivable - Long Term | 0.266 | 0 | ||||
Other Long Term Assets, Total | 10.488 | 6.581 | 0.793 | 8.752 | 10.436 | 9.53 |
Total Current Liabilities | 30.689 | 28.84 | 21.819 | 13.023 | 10.283 | 9.85 |
Accounts Payable | 3.984 | 3.771 | 4.433 | 3.579 | 1.965 | 3.448 |
Accrued Expenses | 7.883 | 10.379 | 9.228 | 8.553 | 6.301 | 5.859 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7.997 | 4.788 | 0 | 1.228 | 0 | |
Other Current Liabilities, Total | 10.825 | 9.902 | 8.158 | 0.891 | 0.789 | 0.543 |
Total Liabilities | 58.379 | 71.403 | 70.786 | 19.244 | 16.689 | 17.227 |
Total Long Term Debt | 4.995 | 8.385 | 28.937 | 0 | 1.587 | 0 |
Long Term Debt | 4.995 | 8.385 | 28.937 | 0 | 1.587 | 0 |
Deferred Income Tax | 10.397 | 8.389 | 4.72 | 1.392 | 0 | |
Other Liabilities, Total | 12.298 | 25.789 | 15.31 | 4.829 | 4.819 | 7.377 |
Total Equity | 117.87 | 178.848 | 168.521 | 55.535 | 61.569 | 169.246 |
Common Stock | 0.115 | 0.199 | 0.216 | 0.021 | 0.116 | 0.235 |
Additional Paid-In Capital | 426.609 | 621.261 | 676.373 | 720.484 | 781.397 | 954.649 |
Retained Earnings (Accumulated Deficit) | -302.844 | -447.64 | -509.406 | -663.6 | -722.912 | -785.374 |
Treasury Stock - Common | -0.241 | 0 | ||||
Other Equity, Total | -5.769 | 5.028 | 1.338 | -1.37 | 2.968 | -0.264 |
Total Liabilities & Shareholders’ Equity | 176.249 | 250.251 | 239.307 | 74.779 | 78.258 | 186.473 |
Total Common Shares Outstanding | 8.89867 | 15.3288 | 16.6413 | 20.6913 | 116.231 | 235.219 |
Short Term Investments | 51.79 | 0 | 80.262 | |||
Redeemable Preferred Stock | 0 | 0 | ||||
Total Preferred Shares Outstanding | 0 | |||||
Other Current Assets, Total | 0.957 | |||||
Long Term Investments | 37.435 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 182.325 | 174.007 | 134.807 | 113.297 | 118.684 |
Cash and Short Term Investments | 165.245 | 157.078 | 117.751 | 98.391 | 103.741 |
Cash & Equivalents | 165.245 | 157.078 | 59.779 | 18.129 | 24.828 |
Total Receivables, Net | 2.306 | 0.96 | 2.266 | 2.06 | 1.841 |
Accounts Receivable - Trade, Net | 2.306 | 0.96 | 0.955 | 0.749 | 0.53 |
Total Inventory | 11.181 | 12.523 | 11.954 | 8.634 | 9.141 |
Other Current Assets, Total | 3.593 | 3.446 | 0.627 | 0.957 | 0.935 |
Total Assets | 223.615 | 212.004 | 199.759 | 186.473 | 166.56 |
Property/Plant/Equipment, Total - Net | 13.413 | 13.975 | 14.239 | 16.319 | 15.523 |
Intangibles, Net | 18.591 | 15.943 | 12.82 | 9.892 | 7.009 |
Other Long Term Assets, Total | 9.286 | 8.079 | 7.751 | 9.53 | 10.617 |
Total Current Liabilities | 9.508 | 8.307 | 9.421 | 9.85 | 8.653 |
Accounts Payable | 2.327 | 2.653 | 3.231 | 3.448 | 3.521 |
Accrued Expenses | 3.83 | 4.868 | 5.512 | 5.859 | 4.599 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.459 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 0.892 | 0.786 | 0.678 | 0.543 | 0.533 |
Total Liabilities | 17.697 | 16.443 | 18.258 | 17.227 | 15.735 |
Total Long Term Debt | 0.356 | 0 | 0 | 0 | 0 |
Long Term Debt | 0.356 | 0 | 0 | 0 | |
Other Liabilities, Total | 7.833 | 8.136 | 8.837 | 7.377 | 7.082 |
Total Equity | 205.918 | 195.561 | 181.501 | 169.246 | 150.825 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.233 | 0.234 | 0.234 | 0.235 | 0.236 |
Additional Paid-In Capital | 944.907 | 947.249 | 950.242 | 954.649 | 956.557 |
Retained Earnings (Accumulated Deficit) | -740.252 | -753.424 | -769.493 | -785.374 | -804.502 |
Other Equity, Total | 1.03 | 1.502 | 0.518 | -0.264 | -1.466 |
Total Liabilities & Shareholders’ Equity | 223.615 | 212.004 | 199.759 | 186.473 | 166.56 |
Total Common Shares Outstanding | 232.717 | 234.231 | 234.37 | 235.219 | 236.415 |
Total Preferred Shares Outstanding | 0 | 0 | |||
Short Term Investments | 57.972 | 80.262 | 78.913 | ||
Prepaid Expenses | 2.209 | 3.255 | 3.026 | ||
Long Term Investments | 30.142 | 37.435 | 14.727 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Cash From Operating Activities | -52.386 | -47.295 | -48.493 | -73.484 | -46.675 | -40.659 |
Cash From Operating Activities | 1.942 | 2.486 | 2.42 | 2.166 | 2.898 | 2.857 |
Amortization | 6.967 | 7.858 | 10.868 | 10.301 | 10.801 | 11.254 |
Deferred Taxes | -5.562 | -3.3 | -3.377 | -3.224 | -1.516 | 0.225 |
Non-Cash Items | 70.148 | 94.494 | 9.288 | 76.825 | 11.171 | 6.24 |
Cash Interest Paid | 1.289 | 0.899 | 1.73 | 2.187 | 0 | 0 |
Changes in Working Capital | -5.901 | -4.037 | -5.915 | -5.351 | -10.717 | 1.227 |
Cash From Investing Activities | -1.361 | 5.509 | -53.481 | 67.645 | -0.003 | -119.668 |
Capital Expenditures | -1.361 | -1.991 | -0.77 | -0.437 | -0.003 | -1.368 |
Cash From Financing Activities | 49.943 | 104.371 | 26.452 | -5.609 | 53.37 | 161.705 |
Financing Cash Flow Items | -1.35 | -7.349 | -2.432 | -0.499 | -0.11 | -1.063 |
Issuance (Retirement) of Stock, Net | 58.195 | 112.058 | 15.682 | 26.315 | 50.665 | 162.768 |
Issuance (Retirement) of Debt, Net | -6.902 | -0.338 | 13.202 | -31.425 | 2.815 | 0 |
Foreign Exchange Effects | -0.055 | 0.431 | -0.433 | 0.364 | 0.27 | 0.376 |
Net Change in Cash | -3.859 | 63.016 | -75.955 | -11.084 | 6.962 | 1.754 |
Other Investing Cash Flow Items, Total | 7.5 | -52.711 | 68.082 | 0 | -118.3 | |
Cash Taxes Paid | -0.17 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -17.34 | -30.512 | -46.581 | -62.462 | -19.128 |
Cash From Operating Activities | -10.237 | -18.485 | -27.487 | -40.659 | -15.943 |
Cash From Operating Activities | 0.802 | 1.585 | 2.416 | 2.857 | 0.869 |
Amortization | 2.867 | 5.729 | 8.533 | 11.254 | 2.67 |
Deferred Taxes | -0.038 | -0.036 | -0.004 | 0.225 | 0.084 |
Non-Cash Items | 4.146 | 3.785 | 5.867 | 6.24 | 2.303 |
Changes in Working Capital | -0.674 | 0.964 | 2.282 | 1.227 | -2.741 |
Cash From Investing Activities | -0.395 | -0.7 | -89.07 | -119.668 | 23.045 |
Capital Expenditures | -0.395 | -0.7 | -0.838 | -1.368 | -0.246 |
Cash From Financing Activities | 159.605 | 160.108 | 160.141 | 161.705 | -0.336 |
Financing Cash Flow Items | -0.214 | -1.041 | -1.058 | -1.063 | -0.348 |
Issuance (Retirement) of Stock, Net | 159.819 | 161.149 | 161.199 | 162.768 | 0.012 |
Foreign Exchange Effects | -0.108 | -0.329 | -0.181 | 0.376 | -0.045 |
Net Change in Cash | 148.865 | 140.594 | 43.403 | 1.754 | 6.721 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Other Investing Cash Flow Items, Total | -88.232 | -118.3 | 23.291 | ||
Cash Interest Paid | 0 | ||||
Cash Taxes Paid | -0.029 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.8268 | 11431792 | 575904 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5426 | 3653424 | -20584 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.1492 | 2721843 | -2318995 | 2022-09-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9254 | 2191771 | 4666 | 2022-09-30 | LOW |
GSA Capital Partners LLP | Hedge Fund | 0.4227 | 1001158 | 629411 | 2022-09-30 | HIGH |
Ergoteles Capital | Hedge Fund | 0.4087 | 967987 | -75876 | 2022-09-30 | HIGH |
Fernando (Anthony C J) | Individual Investor | 0.3475 | 823117 | 0 | 2022-04-18 | |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.345 | 817129 | 0 | 2022-12-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.308 | 729462 | -243844 | 2022-09-30 | LOW |
Milne David Bruce | Individual Investor | 0.2617 | 619884 | 0 | 2022-04-18 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.2491 | 590010 | 171230 | 2022-09-30 | LOW |
SV Health Investors, LLC | Venture Capital | 0.2154 | 510142 | 0 | 2022-09-30 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1753 | 415150 | 0 | 2022-09-30 | LOW |
Hsiao (Jane H) | Individual Investor | 0.1422 | 336895 | 0 | 2022-04-18 | |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 0.125 | 296100 | 296100 | 2022-09-30 | MED |
DWS Investment Management Americas, Inc. | Investment Advisor/Hedge Fund | 0.1219 | 288600 | 0 | 2022-09-30 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.1196 | 283376 | -237674 | 2022-09-30 | MED |
Advisor Group, Inc | Investment Advisor | 0.0903 | 213840 | 22666 | 2022-09-30 | LOW |
Caption Management, LLC | Hedge Fund | 0.085 | 201243 | 0 | 2022-09-30 | HIGH |
Biffi (Andrea) | Individual Investor | 0.0843 | 199738 | 0 | 2022-04-18 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Asensus Surgical, Inc. Company profile
Asensus Surgical (ASXC) is a medical device company that engages in digitising the interface between the surgeon and the patient to improve minimally invasive surgery (MIS).
Founded in 2006, Asensus is headquartered in Durham, North Carolina. It pioneers a new era of performance-guided surgery, using advanced capabilities, like machine vision, augmented intelligence, connectivity and robotics in laparoscopy.
Asensus has built the foundation of Digital Laparoscopy with the help of its Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to address clinical, cognitive and economic shortcomings in surgery.
The Senhance Surgical System is a multi-port robotic system that provides enhanced control with surgeon eye-tracking camera control & 3D (three dimensional) HD (high definition) vision and enhances precision through tremor filtrations and robotic stabilisation. Additionally, surgeons can have enhanced focus during surgery through Asensus’s optimised ergonomics and the sense of touch (haptics).
The surgical device that consists of a robotic instrument and a camera for laparoscopic procedures is considered to be the smallest instrument offered in robotics, leading to smaller incisions than traditional robotic surgery. Asensus’ Senhance ultrasonic system is an advanced energy device to deliver controlled energy to ligate and divide tissue.
Asensus Surgical previously developed the SPIDER device and the SurgiBot System. It changed its name from TransEnterix in February 2021. The company went public as TransEnterix in May 2014. It trades on the NYSE American under the ticker ‘ASXC’.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
1 Tw Alexander Drive
Suite 160
DURHAM
NORTH CAROLINA 27703
US
Income Statement
- Annual
- Quarterly
News

Markets look for guidance after Powell speech, eyeing US CPI: USD, S&P 500, DAX 40
Us equities try to build appetite to push higher after Powell acknowledges disinflation during his speech
12:34, 8 February 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
15:00, 7 February 2023
Gold Price Forecast: Gold Loses Shine as USD and US Yields Edge Higher
Gold correcting lower on USD comeback. Eyes on Chair Powell to exacerbate Gold downside
12:41, 7 February 2023
Australian Dollar Outlook: AUD/USD bounces back as RBA hikes 25bps
AUS/USD bounces higher as RBA delivers its 9th rate hike
11:28, 7 February 2023
Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields
Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.
14:36, 6 February 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com